Genentech Inc, a US biotechnology research company, plans to found a research joint venture with the Taiwanese government in Hsinchu to develop AIDS treatments headed by Taiwanese-American researcher David Ho (何大一), Chinese-language news-papers said yesterday.
Ho has reportedly agreed to serve as chairman of the planned joint-venture -- to be known as TaiMed -- which is to be set up in Hsinchu Biochemical Science Park (新竹生醫科學園區), reports quoted Liang Chi-ming (梁啟銘), director of the Office of Public Affairs at the Academia Sinica, as saying.
Academia Sinica is the nation's top research institute.
South San Francisco-based Genentech will transfer its CD4 antibody technology to TaiMed, the United Daily News said, citing Liang.
CD4, which exists on the membrane of T cells, is a primary receptor used by HIV-1 to gain entry into host T cells, which plays an essential role in cell-mediated immunity and targets of HIV infection. If developed successfully, the CD4 antibody will block CD4 from destroying the immune system.
Funding for the joint-venture should reach NT$3 billion (US$90.5 million) for the first three years, with the Cabinet's Development Fund investing in as much as 45 percent of that, the paper quoted Liang as saying. The rest of the funds will come from private enterprises and venture capital, the paper said.
The China Times carried a similar report yesterday, citing Council for Economic Planning and Development chairwoman Ho Mei-yueh (
But the government investment will not exceed 45 percent, or the company would become state-run, Ho said in the report.
Liang said that the project was initiated by Academia Sinica President Wong Chi-huey (翁啟惠), who hopes to establish a research firm to attract overseas Taiwanese biotech researchers back to the nation.
Ho, well-known for pioneering the use of protease inhibitors in treating HIV-infected patients with his team, will be hired as a researcher by the Academia Sinica and then assume the chairmanship of TaiMed, the reports said, quoting Liang.
The CD4 treatment, along with Ho's cocktail drug for curbing AIDS in its early period, will be the focus at TaiMed, Liang said.
If the new drug is successful, TaiMed could earn royalties from drug manufacturers and obtain sales right in East Asia, he said.
The legislature passed the Biotech and New Pharmaceutical Development Act (生技新藥產業發展條例) last Friday, which allows government researchers to transfer their knowledge to private companies developing new drugs.
STAYING AHEAD: Fitch said that TSMC remains technologically ahead of others, but Samsung is building a new chip fab, while China is investing in its domestic industry As escalating US-China tensions and COVID-19-related production disruptions force US technology supply chains to transform, Taiwan Semiconductor Manufacturing Co’s (TSMC, 台積電) US$12 billion chip fabrication plant in Arizona would be key to spurring greater US production of core semiconductor components, Fitch Ratings said. “We view the US-TSMC alliance as a first step in building a more autonomous US technology supply chain, given high barriers to entry, specifically related to the significant capital and design capability required for leading-edge semiconductor manufacturing,” Fitch said in a statement on Tuesday. “By working with TSMC, US chipmakers will not face the financial burden of incremental investment
DIVERSIFICATION: Although COVID-19 would push more companies to produce in emerging markets, DBS said that it was unlikely that firms would totally leave China Geopolitical tensions and supply disruptions are expected to accelerate the migration of manufacturing out of China, as concerns about the risk of production concentrated in one country increase, S&P Global Ratings said. Although its economic expansion might be weaker than previous levels due to the accelerated relocation of manufacturing, China’s economic growth would still be stronger than that of most other economies, the ratings agency said. “While absolute growth rates will moderate, we believe China’s economic performance will continue to be a key sovereign credit support,” S&P Global Ratings credit analyst Tan Kim Eng (陳錦榮) said in a statement on Thursday. “Its growth
Taiwan’s corporate landscape has changed significantly over the past 20 years, with Hon Hai Precision Industry Co (鴻海精密) replacing Formosa Plastics Corp (台塑) as the revenue leader, while Taiwan Semiconductor Manufacturing Co. (TSMC, 台積電) has emerged as the most profitable firm, a survey of Taiwan’s 50 largest companies published on Tuesday last week showed. The Chinese-language CommonWealth Magazine survey ranked Taiwan’s 50 largest companies based on their revenue last year, and compared them with the results of a similar survey it conducted in 2000. Only 33 companies on the original list remained in this year’s rankings, the survey found, following two
GEOPOLITICAL RISKS: Beijing announced plans to strengthen ‘enforcement’ in Hong Kong, sparking losses across Asia led by the Hang Seng’s 5.6 percent plunge Local shares on Friday ended sharply lower amid renewed tensions between the US and China over Chinese telecommunications equipment giant Huawei Technologies Co Ltd (華為) and China’s plan to introduce a national security law in Hong Kong. The TAIEX on Friday finished down 197.16, or 1.79 percent, at 10,811.15 on turnover of NT$177.183 billion (US$5.9 billion), almost flat from a close of 10,814.92 on May 15. The market was down across all major sectors, in particular electronics shares, which finished down 1.99 percent from Thursday’s close. Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), the world’s largest wafer foundry and a chip supplier